MIAMI--(BUSINESS WIRE)--April 7, 2006--DOR BioPharma, Inc. (AMEX:DOR - News; "DOR", or the "Company") announced today the first successful evaluation in animal tests of a nasal, bivalent combination of its botulinum toxin vaccine, BT-VACC(TM), addressing two of the most prevalent serotypes of botulinum toxin, types A and B. DOR is designing BT-VACC(TM) to be administered by the mucosal route, which offers significant advantages to the end user in terms of increased safety, lack of pain from injections, and ability to induce protective antibodies in the lung and intestines. These types of antibodies are associated with inactivation of botulinum toxins before they enter the body. These results are the first ever report of a combination of botulinum vaccine serotypes given by the mucosal route.
